{"protocolSection": {"identificationModule": {"nctId": "NCT00433836", "orgStudyIdInfo": {"id": "CVAL489K2302"}, "organization": {"fullName": "Novartis", "class": "INDUSTRY"}, "briefTitle": "Effect of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children With High Blood Pressure", "officialTitle": "A Multicenter, Randomized, Double-blind, Parallel-group, Evaluation of 12 Weeks of Valsartan Compared to Enalapril on Sitting Systolic Blood Pressure in Children 6 to 17 Years of Age With Hypertension"}, "statusModule": {"statusVerifiedDate": "2011-04", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2007-01"}, "primaryCompletionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "completionDateStruct": {"date": "2009-02", "type": "ACTUAL"}, "studyFirstSubmitDate": "2007-02-08", "studyFirstSubmitQcDate": "2007-02-09", "studyFirstPostDateStruct": {"date": "2007-02-12", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2010-12-08", "resultsFirstSubmitQcDate": "2011-04-19", "resultsFirstPostDateStruct": {"date": "2011-05-19", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2011-04-19", "lastUpdatePostDateStruct": {"date": "2011-05-19", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"oldNameTitle": "External Affairs", "oldOrganization": "Novartis Pharmaceuticals"}, "leadSponsor": {"name": "Novartis Pharmaceuticals", "class": "INDUSTRY"}}, "descriptionModule": {"briefSummary": "The purpose of this 12-week active controlled trial is to evaluate the safety and efficacy of valsartan 80/160/320 mg (weight stratified) compared with enalapril 10/20/40 mg (weight stratified) on sitting systolic blood pressure (SSBP) in 6 - 17 year old children with hypertension (SSBP \u2265 95th percentile for age gender and height)."}, "conditionsModule": {"conditions": ["Hypertension"], "keywords": ["Children", "pediatrics", "High Blood Pressure", "Hypertension", "Valsartan", "enalapril"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "TRIPLE", "whoMasked": ["PARTICIPANT", "CARE_PROVIDER", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 300, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Valsartan 80 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan"]}, {"label": "Valsartan 160 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan"]}, {"label": "Valsartan 320 mg", "type": "EXPERIMENTAL", "interventionNames": ["Drug: Valsartan"]}, {"label": "Enalapril 10 mg", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Enalapril"]}, {"label": "Enalapril 20 mg", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Enalapril"]}, {"label": "Enalapril 40 mg", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Enalapril"]}], "interventions": [{"type": "DRUG", "name": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.", "armGroupLabels": ["Valsartan 160 mg", "Valsartan 320 mg", "Valsartan 80 mg"]}, {"type": "DRUG", "name": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.", "armGroupLabels": ["Enalapril 10 mg", "Enalapril 20 mg", "Enalapril 40 mg"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)", "description": "Mean sitting systolic blood pressure (MSSBP) change after 12 weeks of treatment measured by office blood pressure measurement.", "timeFrame": "Baseline and Week 12"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)", "description": "The change from baseline in mean sitting diastolic blood pressure (MSDBP) after 12 weeks of treatment as measured by office blood pressure.", "timeFrame": "Baseline and Week 12"}, {"measure": "Decrease in MSSBP to < 95th Percentile for Age, Gender and Height", "description": "The percentage of children whose MSSBP decreased to \\<95th percentile for age, gender, and height on valsartan vs. enalapril monotherapy at week 12.", "timeFrame": "at week 12"}, {"measure": "Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients", "description": "The effect of valsartan and enalapril between baseline and visit 6 on 24-hour mean ambulatory systolic and diastolic blood pressure (ASBP, ADBP) in a subset of patients.", "timeFrame": "Baseline and Week 8"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Male or female, ages 6-17, with a documented history of hypertension\n* Must be able to swallow a pill\n* Must be \u2265 18 kg or \u2264160 kg\n* MSSBP (mean of 3 measurements) must be \u2265 95th percentile, for age, gender and height, at Visit 2 (randomization), by office blood pressure measurement\n* Patients who are eligible and able to participate in the study and whose parent(s)/guardian(s) consent in writing (written informed consent) to their doing so after the purpose and nature of the investigation has been clearly explained to them. (An assent will be required for some patients depending upon their age and local requirements regarding assents)\n\nExclusion Criteria:\n\n* Renal artery stenosis\n* Current diagnosis of heart failure (NYHA Class II-IV).\n* MSSBP \u2265 25% above the 95th percentile\n* Second or third degree heart block without a pacemaker.\n* Concurrent potentially life threatening arrhythmia or symptomatic arrhythmia.\n* Clinically significant valvular heart disease.\n* Patient that demonstrates clinically significant ECG abnormalities other than those associated with left ventricular hypertrophy.\n* Previous solid organ transplantation except renal, liver or heart transplantation. Renal, liver or heart transplant must have occurred at least 6 months prior to enrollment. Patient must be on stable doses of immunosuppressive therapy for 3 months and deemed clinically stable by the investigator.\n\nOther protocol-defined inclusion/exclusion criteria may apply", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "6 Years", "maximumAge": "17 Years", "stdAges": ["CHILD"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Novartis Pharmaceuticals", "affiliation": "Novartis Pharmaceuticals", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "Sites in USA", "city": "East Hanover", "state": "New Jersey", "zip": "07936", "country": "United States", "geoPoint": {"lat": 40.8201, "lon": -74.36487}}, {"facility": "Sites in Belgium", "city": "Sites in Belgium", "country": "Belgium"}, {"facility": "Sites in France", "city": "Sites in France", "country": "France"}, {"facility": "Sites in Germany", "city": "Sites in Germany", "country": "Germany"}, {"facility": "Sites in Hungary", "city": "Hungary", "country": "Hungary"}, {"facility": "Sites in India", "city": "Sites in India", "country": "India"}, {"facility": "Sites in Italy", "city": "Sites in Italy", "country": "Italy"}, {"facility": "Sites in Poland", "city": "Poland", "country": "Poland"}, {"facility": "Sites in Slovakia", "city": "Slovakia", "country": "Slovakia"}, {"facility": "Sites in Sweden", "city": "Sites in Sweden", "zip": "00000", "country": "Sweden"}, {"facility": "Sites in Turkey", "city": "Turkey", "country": "Turkey"}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg."}, {"id": "FG001", "title": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "151"}, {"groupId": "FG001", "numSubjects": "149"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "138"}, {"groupId": "FG001", "numSubjects": "143"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "13"}, {"groupId": "FG001", "numSubjects": "6"}]}], "dropWithdraws": [{"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "7"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "3"}, {"groupId": "FG001", "numSubjects": "0"}]}, {"type": "Withdrawal by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "2"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Unsatisfactory therapeutic effect", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Protocol Violation", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}]}, {"type": "Condition no longer requires study drug", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}, {"type": "Abnormal laboratory values", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg."}, {"id": "BG001", "title": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg."}, {"id": "BG002", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "151"}, {"groupId": "BG001", "value": "149"}, {"groupId": "BG002", "value": "300"}]}], "measures": [{"title": "Age Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "12.7", "spread": "2.93"}, {"groupId": "BG001", "value": "13.0", "spread": "2.94"}, {"groupId": "BG002", "value": "12.9", "spread": "2.93"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "65"}, {"groupId": "BG001", "value": "44"}, {"groupId": "BG002", "value": "109"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "86"}, {"groupId": "BG001", "value": "105"}, {"groupId": "BG002", "value": "191"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Mean Sitting Systolic Blood Pressure (MSSBP)", "description": "Mean sitting systolic blood pressure (MSSBP) change after 12 weeks of treatment measured by office blood pressure measurement.", "populationDescription": "Intent-to-treat. Only patients who had both baseline and endpoint values are included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg."}, {"id": "OG001", "title": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-15.4", "spread": "1.29"}, {"groupId": "OG001", "value": "-14.1", "spread": "1.28"}]}]}], "analyses": [{"groupIds": ["OG000", "OG001"], "testedNonInferiority": true, "nonInferiorityType": "NON_INFERIORITY_OR_EQUIVALENCE", "nonInferiorityComment": "non-inferiority delta of 3.5 mm Hg", "statisticalMethod": "ANOVA", "paramType": "Mean Difference (Final Values)", "paramValue": "-1.3", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "-3.80", "ciUpperLimit": "1.17"}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Sitting Diastolic Blood Pressure (MSDBP)", "description": "The change from baseline in mean sitting diastolic blood pressure (MSDBP) after 12 weeks of treatment as measured by office blood pressure.", "populationDescription": "Intent-to-treat. Only patients who had both baseline and endpoint values are included.", "reportingStatus": "POSTED", "paramType": "LEAST_SQUARES_MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 12", "groups": [{"id": "OG000", "title": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg."}, {"id": "OG001", "title": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "-9.4", "spread": "0.94"}, {"groupId": "OG001", "value": "-8.5", "spread": "0.95"}]}]}]}, {"type": "SECONDARY", "title": "Decrease in MSSBP to < 95th Percentile for Age, Gender and Height", "description": "The percentage of children whose MSSBP decreased to \\<95th percentile for age, gender, and height on valsartan vs. enalapril monotherapy at week 12.", "populationDescription": "Intent-to-treat. Only patients who had both baseline and endpoint values are included.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "at week 12", "groups": [{"id": "OG000", "title": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg."}, {"id": "OG001", "title": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "148"}, {"groupId": "OG001", "value": "148"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "66.9"}, {"groupId": "OG001", "value": "70.3"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Mean Ambulatory Systolic Blood Pressure (ASBP) and Mean Ambulatory Diastolic Blood Pressure (ADBP) Over 24 Hours in Subset of Patients", "description": "The effect of valsartan and enalapril between baseline and visit 6 on 24-hour mean ambulatory systolic and diastolic blood pressure (ASBP, ADBP) in a subset of patients.", "populationDescription": "A subset of approximately 100 - 150 patients from selected centers was expected to undergo Ambulatory Blood Pressure Monitoring at baseline (Week 0) and at Week 8; however, only 56 patients chose to participate in this aspect of the study.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "mm Hg", "timeFrame": "Baseline and Week 8", "groups": [{"id": "OG000", "title": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg."}, {"id": "OG001", "title": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "26"}, {"groupId": "OG001", "value": "30"}]}], "classes": [{"title": "ASBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.8", "spread": "6.75"}, {"groupId": "OG001", "value": "-6.8", "spread": "7.41"}]}]}, {"title": "ADBP", "categories": [{"measurements": [{"groupId": "OG000", "value": "-9.3", "spread": "6.27"}, {"groupId": "OG001", "value": "-5.5", "spread": "5.73"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "description": "Includes all patients who received at least one dose of post-randomization study drug; patients were analyzed according to the actual treatment received.", "eventGroups": [{"id": "EG000", "title": "Valsartan", "description": "Weight stratified dosages given by mouth, once daily, of valsartan 80/160/320 mg.", "seriousNumAffected": 3, "seriousNumAtRisk": 151, "otherNumAffected": 42, "otherNumAtRisk": 151}, {"id": "EG001", "title": "Enalapril", "description": "Weight stratified dosages given by mouth, once daily, of enalapril 10/20/40 mg.", "seriousNumAffected": 2, "seriousNumAtRisk": 148, "otherNumAffected": 52, "otherNumAtRisk": 148}], "seriousEvents": [{"term": "Avulsion fracture", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 148}]}, {"term": "Renal injury", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 148}]}, {"term": "Dehydration", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Hyperkalaemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}, {"term": "Brain injury", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 148}]}], "otherEvents": [{"term": "Nasopharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 8, "numAtRisk": 148}]}, {"term": "Pharyngitis", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 6, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 11, "numAtRisk": 148}]}, {"term": "Upper respiratory tract infection", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 7, "numAtRisk": 148}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 28, "numAtRisk": 148}]}, {"term": "Cough", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 9, "numAtRisk": 151}, {"groupId": "EG001", "numAffected": 10, "numAtRisk": 148}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "The terms and conditions of Novartis' agreements with its investigators may vary. However, Novartis does not prohibit any investigator from publishing. Any publications from a single-site are postponed until the publication of the pooled data (i.e., data from all sites) in the clinical trial."}, "pointOfContact": {"title": "Study Director", "organization": "Novartis Pharmaceuticals", "phone": "862-778-8300"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-07-01", "removedCountries": ["Argentina", "Brazil", "Chile", "Czech Republic", "Korea, Republic of", "Lithuania", "Russian Federation", "South Africa", "Switzerland", "United Kingdom"]}, "conditionBrowseModule": {"meshes": [{"id": "D000006973", "term": "Hypertension"}], "ancestors": [{"id": "D000014652", "term": "Vascular Diseases"}, {"id": "D000002318", "term": "Cardiovascular Diseases"}], "browseLeaves": [{"id": "M10024", "name": "Hypertension", "asFound": "Hypertension", "relevance": "HIGH"}, {"id": "M27583", "name": "Systolic Murmurs", "relevance": "LOW"}, {"id": "M17400", "name": "Vascular Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC14", "name": "Heart and Blood Diseases"}, {"abbrev": "All", "name": "All Conditions"}, {"abbrev": "BC23", "name": "Symptoms and General Pathology"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000068756", "term": "Valsartan"}, {"id": "D000004656", "term": "Enalapril"}], "ancestors": [{"id": "D000000959", "term": "Antihypertensive Agents"}, {"id": "D000047228", "term": "Angiotensin II Type 1 Receptor Blockers"}, {"id": "D000057911", "term": "Angiotensin Receptor Antagonists"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000806", "term": "Angiotensin-Converting Enzyme Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}], "browseLeaves": [{"id": "M301", "name": "Valsartan", "asFound": "Extended", "relevance": "HIGH"}, {"id": "M7822", "name": "Enalapril", "asFound": "Box", "relevance": "HIGH"}, {"id": "M18330", "name": "Enalaprilat", "relevance": "LOW"}, {"id": "M4277", "name": "Antihypertensive Agents", "relevance": "LOW"}, {"id": "M4132", "name": "Angiotensin II", "relevance": "LOW"}, {"id": "M289354", "name": "Giapreza", "relevance": "LOW"}, {"id": "M4135", "name": "Angiotensinogen", "relevance": "LOW"}, {"id": "M25789", "name": "Angiotensin II Type 1 Receptor Blockers", "relevance": "LOW"}, {"id": "M28916", "name": "Angiotensin Receptor Antagonists", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4134", "name": "Angiotensin-Converting Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "AnAg", "name": "Antihypertensive Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "VaCoAg", "name": "Vasoconstrictor Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}